Why Johnson & Johnson Will Be a Bigger Winner With Boosters Than Pfizer and Moderna

·4-min read
Why Johnson & Johnson Will Be a Bigger Winner With Boosters Than Pfizer and Moderna

It's looking like COVID-19 boosters will go three-for-three in winning authorizations. An advisory committee to the U.S. Food and Drug Administration (FDA) voted unanimously last week in support of boosters for Moderna's (NASDAQ: MRNA) COVID-19 vaccine and for Johnson & Johnson's (NYSE: JNJ) vaccine. The FDA has already granted Emergency Use Authorization (EUA) to boosters for the COVID-19 vaccine marketed by Pfizer (NYSE: PFE) and its partner BioNTech (NASDAQ: BNTX).

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting